PEG-NUSTIM® is used to prevent neutropenia (a lack of certain white blood cells) arising as a result of chemotherapy administration
PEG-NUSTIM® is indicated to decrease the risk of patients developing febrile neutropenia when receiving myelosuppressive chemotherapy regimens and is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.
It is a prefilled syringe containing single dose of 6 mg/0.6 ml for subcutaneous use.
Long-acting G-CSFs (Pegfilgrastim) have been modified to increase molecular size and thus evade clearance by the kidneys. Instead of renal clearance, long-acting G-CSFs are cleared from the body predominantly by circulating neutrophils. As a result, serum levels of long-acting G-CSFs remain high during neutropenia but decrease as neutrophil levels return to normal.
Copyright ©2025. All Rights Reserved
